Actinium Pharmaceuticals to Showcase Capabilities of its AWE Technology Platform in Developing Biobetters at Upcoming AACR Annual ...
- In vivo data to be presented via poster highlighting the ability of Actinium’s AWE Technology to yield increased cell killing power, survival benefit and a potential biobetter of daratumumab, a blockbuster CD38 targeted therapy for multiple myeloma - …